Literature DB >> 11464439

Treating obesity: a new target for prevention of coronary heart disease.

L J Aronne1.   

Abstract

Recognition by the American Heart Association that obesity is a major modifiable risk factor for coronary heart disease has prompted health providers to take a more active role in obesity management. Obesity has long been known to accompany a host of chronic diseases, e.g., type II diabetes, hypertension, and dyslipidemia. We now recognize that obesity is itself a chronic disease with a complex etiology; like diabetes and hypertension, it is treatable with a similar chronic disease treatment model. Relatively modest weight loss confers disproportionate health benefits, improving a roster of risk factors. Diet, exercise, and behavior modification still compose the gold standard of treatment. If these measures fail, medication and surgery should be considered for appropriate patients. With current techniques, many patients can achieve realistic weight goals that can be maintained over the long term. Published management guidelines can now assist in integrating the practical applications of obesity-related research findings into everyday clinical practice.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11464439     DOI: 10.1111/j.0889-7204.2001.00589.x

Source DB:  PubMed          Journal:  Prog Cardiovasc Nurs        ISSN: 0889-7204


  3 in total

1.  Pro-HEART - a randomized clinical trial to test the effectiveness of a high protein diet targeting obese individuals with heart failure: rationale, design and baseline characteristics.

Authors:  Marjan Motie; Lorraine S Evangelista; Tamara Horwich; Michele Hamilton; Dawn Lombardo; Dan M Cooper; Pietro R Galassetti; Gregg C Fonarow
Journal:  Contemp Clin Trials       Date:  2013-08-17       Impact factor: 2.226

2.  Reduced body weight and adiposity with a high-protein diet improves functional status, lipid profiles, glycemic control, and quality of life in patients with heart failure: a feasibility study.

Authors:  Lorraine S Evangelista; David Heber; Zhaoping Li; Susan Bowerman; Michele A Hamilton; Gregg C Fonarow
Journal:  J Cardiovasc Nurs       Date:  2009 May-Jun       Impact factor: 2.083

3.  Potential benefits of L. acidophilus in dyslipidemic rats.

Authors:  Onrapak Reamtong; Tipparat Thiangtrongjit; Nathamon Kosoltanapiwat; Watanalai Panbangred; Pattaneeya Prangthip
Journal:  Sci Rep       Date:  2021-03-17       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.